The aim of this study was to determine if once daily insulin detemir reverses decline in weight and lung function in patients with cystic fibrosis (CF). 12 patients with early insulin deficiency and six with CF related diabetes (aged 7.2–18.1 years) were treated for a median of 0.8 years. Changes in weight and lung function following treatment were compared to pretreatment changes. Before treatment, the change in weight SD score (ΔWtSDS), percentage of predicted forced expiratory volume in 1 s (Δ%FEV1) and percentage of predicted forced vital capacity (Δ%FVC) declined in the whole study population (−0.45±0.38, −7.9±12.8%, −5.8±14.3%) and in the subgroup with early insulin deficiency (−0.41±0.43, −9.8±9.3%, −6.8±10.3%). Following treatment with insulin ΔWtSDS, Δ%FEV1 and Δ%FVC significantly improved in the whole study population (+0.18±0.29 SDS, p=0.0001; +3.7±10.6%, p=0.007; +5.2±12.7%, p=0.013) and in patients with early insulin deficiency (+0.22±0.31 SDS, p=0.003; +5.3±11.5%, p=0.004; +5.8±13.4%, p=0.024). Randomised controlled trials are now needed.
Statistics from Altmetric.com
Funding This study was supported by grants from the Sydney Children's Hospital Foundation and the Novo Nordisk Regional Diabetes Support Scheme. SH's fellowship was partly supported by a donation from Novo Nordisk to the Sydney Children's Hospital Foundation. The funding sources played no part in the study design, collection, analysis or interpretation of data, writing of the report, or in the decision to submit the paper for publication.
Competing interests None.
Ethics approval This study was conducted with the approval of the South Eastern Sydney Illawarra Area Health Service, Northern Hospital Network, Research Support Office.
Provenance and peer review Not commissioned; externally peer reviewed.